United Therapeutics Corporation (UTHR) : Smith Asset Management Group Lp reduced its stake in United Therapeutics Corporation by 0.37% during the most recent quarter end. The investment management company now holds a total of 279,156 shares of United Therapeutics Corporation which is valued at $31,600,459 after selling 1,034 shares in United Therapeutics Corporation , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.United Therapeutics Corporation makes up approximately 0.92% of Smith Asset Management Group Lp’s portfolio.
Other Hedge Funds, Including , Candriam Luxembourg S.c.a. reduced its stake in UTHR by selling 4,000 shares or 22.22% in the most recent quarter. The Hedge Fund company now holds 14,000 shares of UTHR which is valued at $1,584,800. United Therapeutics Corporation makes up approx 0.04% of Candriam Luxembourg S.c.a.’s portfolio.Financial Architects Inc reduced its stake in UTHR by selling 13 shares or 44.83% in the most recent quarter. The Hedge Fund company now holds 16 shares of UTHR which is valued at $1,811.New York State Teachers Retirement System reduced its stake in UTHR by selling 1,700 shares or 1.77% in the most recent quarter. The Hedge Fund company now holds 94,279 shares of UTHR which is valued at $10,503,623. United Therapeutics Corporation makes up approx 0.03% of New York State Teachers Retirement System’s portfolio.Acadian Asset Management boosted its stake in UTHR in the latest quarter, The investment management firm added 77,552 additional shares and now holds a total of 1,172,270 shares of United Therapeutics Corporation which is valued at $134,611,764. United Therapeutics Corporation makes up approx 0.67% of Acadian Asset Management’s portfolio.
United Therapeutics Corporation opened for trading at $118.97 and hit $122.23 on the upside on Friday, eventually ending the session at $121.01, with a gain of 1.70% or 2.02 points. The heightened volatility saw the trading volume jump to 8,68,769 shares. Company has a market cap of $5,400 M.
On the company’s financial health, United Therapeutics Corporation reported $4.55 EPS for the quarter, beating the analyst consensus estimate by $ 1.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $3.52. The company had revenue of $412.60 million for the quarter, compared to analysts expectations of $395.00 million. The company’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.
Many Wall Street Analysts have commented on United Therapeutics Corporation. Shares were Downgraded by H.C. Wainwright on Jun 15, 2016 to ” Neutral” and Lowered the Price Target to $ 95 from a previous price target of $175 .United Therapeutics Corporation was Downgraded by Ladenburg Thalmann to ” Neutral” on Apr 29, 2016.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.